Board of Directors


Joseph Blanchard

Joe Blanchard

President and Chief Executive Officer, Amorsa Therapeutics

Mr. Blanchard has co-founded and has been a member of the leadership teams that helped build several life science  companies. Prior to Amorsa, Mr. Blanchard co-founded and served as Chief Operating Officer and Chief Business Officer at Aushon BioSystems, a global provider of protein biomarker detection systems used in drug development and diagnostic applications.

Mr. Blanchard was also an early member of the leadership team for Altus Pharmaceuticals (a spin-out of Vertex Pharmaceuticals and 2006 IPO), where he held several senior management positions. Prior to Altus, he was Director of Sales Operations (The Americas) for Genencor International (2000 IPO; now owned by DuPont), where he led a 40-member commercial team generating over $130 million annually.

Mr. Blanchard was also Senior Vice President, Business Development at Decision Biomarkers and earlier in his career held business unit and sales management positions with Akzo Nobel of the Netherlands and DuPont/Conoco Chemicals. He has an M.B.A and B.S. degree from Miami University.

Anita Gupta

Anita Gupta, D.O., Pharma.D.

Vice Chair, Division of Pain Medicine & Anesthesiology, Drexel University College of Medicine

Dr. Anita Gupta is currently Vice Chair and Associate Professor at Drexel University College of Medicine in the Division of Pain Medicine in the Department of Anesthesiology. She is a board-certified anesthesiologist, pain specialist, pharmacist and an author of top-selling books including “Interventional Pain Medicine” and “Pharmacology in Anesthesia Practice.” As a recognized, international authority on pain medicine, Dr. Gupta has served as a influential medical expert on CNN, Forbes, FOXNEWS, and NBC, The Examiner, Parade, and many more for stories related to a broad range of breaking medical news.

Dr. Gupta currently serves as an advisor to the FDA on the AADPAC Committee, a a founding fellow of the Institute of Coaching at Harvard Medical School/McLean Hospital and has also completed the Wharton Total Leadership Program. She has completed post doctoral education and innovative research training at both National Institutes of Health and Massachusetts Institute of Technology.

She is currently a member of the GIEESC working group of the World Health Organization, founder of Society of Women in Medicine, and has been a consecutive recipient of the Patients Choice and Compassionate Physician Choice Award. She also completed the health advocacy and public policy fellowship with the Mayday Foundation in Washington DC and New York City.

Dr. Gupta continues to lead research efforts that are instrumental to the advancement of pain medicine and anesthesiology and innovations in healthcare. She has earned broad recognition for her research and has been an invited presenter at numerous influential medical and advisory forums.
Dr. Gupta completed her Doctorate in Pharmacy at Rutgers University and her medical degree from University of Medicine and Dentistry of New Jersey and her residency in anesthesiology at Georgetown University Hospital and National Institutes of Health. Following residency, Dr. Gupta completed a pain management fellowship from the Johns Hopkins Medical Institutions and then joined faculty at the University of Pennsylvania.

Alex Nivorozhkin

Alex Nivorozhkin, Ph.D.

Chief Operating Officer, Amorsa Therapeutics

Dr. Nivorozhkin is an experienced life science executive with an extensive track record in early technology development. He was a co-founder of both Boston BioCom, LLC, a biopharmaceuticals company funded by the seed investment from Pfizer, and Neo-Advent Technologies LLC, a drug formulation and delivery technologies company. Dr. Nivorozhkin gained substantial experience in the commercial aspects of drug discovery and development at Epix Medical and Inotek Pharmaceuticals where he served as the company’s Head of Medicinal Chemistry. He served as a Senior Program Manager at the Center of Integration of Medicine and Innovative Technologies (CIMIT) at Massachusetts General Hospital, a consortium of the Harvard Medical School-affiliated hospitals, Boston University, Draper Laboratory and MIT. He was also a Scientific Programs Officer at Sheldon and Miriam Adelson Medical Research Foundation.

Dr. Nivorozhkin is a co-inventor of several drug candidates that have advanced to clinical trials, has co-authored over 60 scientific publications in different areas of chemistry, chemical biology, and material sciences and holds more than 20 patents. He received a Ph.D. in Physical Organic Chemistry from Rostov University and conducted his postdoctoral research at the University Paris-Sud, France, and the Department of Chemistry and Chemical Biology, Harvard University.